NASDAQ $IXHL Announces Positive Pre-IND Meeting wi
Post# of 18216
![Avatar](/images/ProfileImages/982093748_22164_no_avatar_available.jpg)
MELBOURNE, Australia, May 17, 2022 /PRNewswire/ -- Incannex Healthcare Limited (NASDAQ: IXHL) (ASX: IHL), ('Incannex' or the 'Company') a clinical-stage pharmaceutical company developing unique medicinal cannabinoid pharmaceutical products and psychedelic medicine therapies for unmet medical needs, is pleased to announce that it completed a highly constructive Pre-Investigational New Drug Application ('pre-IND') meeting with the U.S. Food and Drug Administration ('FDA') to discuss the development IHL-42X.
https://finance.yahoo.com/news/incannex-annou...00713.html
![Like This Post](/images/thumb-up.png)
![Dislike This Post](/images/thumb-down.png)